Meningococcal polysaccharide-protein conjugate vaccines

International Journal of Infectious Diseases

Volumn 1, Issue 3, 1997, Pages 152-157

  Granoff, Dan M ^a,c   Forrest, Bruce ^a   Rappuoli, Rino ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Oakland Research Institute ^*

^c CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

Author keywords

conjuguate vaccines; meningococcus; polysaccharide

Indexed keywords

MENINGOCOCCUS VACCINE;

ACTIVE IMMUNIZATION; CONFERENCE PAPER; DRUG EFFICACY; DRUG FORMULATION; HUMAN; IMMUNOGENICITY; INFANT; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MENINGOCOCCEMIA; PRESCHOOL CHILD; VACCINE PRODUCTION;

EID: 0030941061     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1201-9712(97)90079-5     Document Type: Conference Paper

References (35)

1. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 1969; 129:1307-1326.
2. Artenstein MS, Gold R, Zimmerly JG, Wyle FA, Schneider H, Harkins C. Prevention of meningococcal disease by group C polysaccharide vaccine. N Engl J Med 1970; 282:417-420.
3. Reingold AL, Broome CV, Hightower AW, et al. Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet 1985; 2:114-118
4. Frasch CE. Meningococcal vaccines: past, present and future. In: Cartwright K, ed. Meningococcal disease. New York: John Wiley & Sons, 1995:245-283.
5. Gold R, Lepow ML, Goldschneider I, Gotschlich EC. Immune response of human infants to polysaccharide vaccines of groups A and C Neisseria meningitidis. J Infect Dis 1977; 136(Suppl):S31-S35.
6. Finne J, Leinonen M, Makela H. Antigenic similarities between brain components and bacteria causing meningitis. Lancet 1983; 2:355-357.
7. Daum RS, Granoff DM Lessons from the evaluation of immunogenicity. In: Ellis RW, Granoff DM, eds. Development and clinical uses of Haemophilus b conjugate vaccines. New York: Marcel Dekker, Inc., 1994:291-312.
8. Weinberg GA, Einhorn MS, Lenoir AA, Granoff PD, Granoff DM. Immunologic priming to capsular polysaccharide in infants immunized with Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine. J Pediatr 1987; 111:22-27.
9. Granoff DM, Anderson EL, Osterholm MT, et al. Differences in the immunogenicity of three Haemophilus influenzae type b conjugate vaccines in infants. J Pediatr 1992; 121:187-194.
10. Granoff DM, Holmes SJ, Osterholm MT, et al Induction of immunologic memory in infants primed with Haemophilus influenzae type b conjugate vaccines. J Infect Dis 1993; 168:663-671.
11. Schlesinger Y, Granoff DM, the Vaccine Study Group. Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. JAMA 1992; 267:1489-1494.
12. Lucas AH, Granoff DM. Functional differences in idiotypically defined IgG1 anti-polysaccharide antibodies elicited by vaccination with Haemophilus influenzae type b polysaccharide-protein conjugates. J Immunol 1995; 154: 4195-4202
13. Takala AK, Eskola J, Leinonen M, et al. Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine. J Infect Dis 1991; 164:982-986.
14. Murphy TV, Pastor P, Medley F, Osterholm MT, Granoff DM. Decreased Haemophilus colonization in children vaccinated with Haemophilus influenzae type b conjugate vaccine. J Pediatr 1993; 122:517-523
15. Murphy TV, White KE, Pastor P, et al. Declining incidence of Haemophilus influenzae type b disease since introduction of vaccination JAMA 1993; 269:246-248.
16. Beuvery EC, Miedema F, van Delft R, Haverkamp K. Preparation and immunochemical characterization of meningococcal serogroup C polysaccharide-tetanus toxoid conjugates as a new generation of vaccines. Infect Immun 1983; 40:39-45.
17. Beuvery EC, Kaaden A, Kanhai V, Leussink AB. Physiochemical and immunological characterization of meningococcal serogroup A polysaccharide-tetanus toxoid conjugates prepared by two methods. Vaccine 1993; 1:31-36.
18. Jennings HJ, Lugowski C. Immunochemistry of serogroups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates. J Immunol 1981; 127:1011-1018.
19. Rennels MB, Edwards KM, Keyserling HL, et al. Immunogenicity and safety of conjugate meningococcal group C vaccine in infants [Abstract 1083]. Pediatr Res 1996; 39:183A.
20. Costantino P, Viti S, Podda A, Velmonte MA, Nencioni L, Rappuoli R. Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C. Vaccine 1992; 10:691-698.
21. Anderson EL, Bowers T, Mink CM, et al. Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults. Infect Immun 1994; 62:3391-3395.
22. MacDonald NE, Halperin S, Law BJ, et al. Biocine® meningococcal C (MenC) conjugate vaccine elicits high titers of serum bactericidal activity in toddlers [SPR Abstract 1053]. Pediatr Res 1996; 39:178A.
23. Twumasi PA Jr, Kumah S, Leach A, et al. A trial of a group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants. J Infect Dis 1995; 171: 632-638.
24. Lieberman JM, Chiu SS, Wong VK, et al. Safety and immunogenicity of serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children. JAMA 1996; 275:1499-1503.
25. Shackley FM, Heath PT, Flamank C, et al. Immunogenicity and reactogenicity of a group C meningococcal conjugate vaccine in British children [Abstract]. Annual Meeting of The Infectious Diseases Society of America, New Orleans, LA, September 18-20,1996
26. Borrow R, Fairley CK, Begg N, Fox AJ, Jones DM, Cartwright KAV. Immunogenicity of a meningococcal serogroup A and C conjugate vaccine in U.K. infants [Abstract]. 10th International Pathogenic Neisseria Conference, Baltimore, 1996.
27. Leach A, Twumasi PA, Kumah S, et al. Induction of immunological memory in Gambian children by immunization in infancy with a group A plus group C meningococcal polysaccharide and protein-conjugate vaccine. J Infect Dis 1997;175:200-204.
28. Lieberman JM, Wong VK, Partridge S, et al. Bivalent A/C meningococcal conjugate vaccine in toddlers: persistence of antibodies and response to a polysaccharide vaccine booster [Abstract]. 10th International Pathogenic Neisseria Conference, Baltimore, September 8-13,1996
29. Devi SJN, Robbins JB, Schneerson R. Antibodies to poly [(2→8)-α-N-acetylneuraminic acid] and poly[(2→9)-α-N-acetylneuraminic acid] are elicited by immunization of mice with Escherichia coli K92 conjugates: potential vaccines for groups B and C meningococci and E. coli K1. Proc Natl Acad Sci 1991; 88:7175-7179
30. Jennings HJ, Roy R, Gamian A. Induction of meningococcal group B polysaccharide-specific IgG antibodies in mice by using an N-propionylated B polysaccharide-tetanus toxoid conjugate vaccine. J Immunol 1986; 137:1708-1713.
31. 197 via adipic acid dihydrazide. Vaccine 1995; 13:463-470.
32. Bartoloni A, Ricci S, Gallo E, et al. Murine monoclonal antibodies to an N-propionylated meningococcal B polysaccharide exhibit heterogeneity with respect to cross-reactivity with N-acetylated meningococcal B polysaccharide and autoreactivity to host polysialyated glycoproteins [Abstract]. 10th International Pathogenic Neisseria Conference, Baltimore, September 8-13,1996.
33. Jennings HJ. Improved meningococcal polysaccharide conjugate vaccine. European patent specification, publication number: 0 504 202 B1, 1995.
34. Jennings HJ. N-Propionylated group B meningococcal polysaccharide glycoconjugate vaccine against group B meningococcal meningitis. Int J Infect Dis 1997, 1:158-164
35. Granoff DM, McHugh YE, Van Nest GA, Raff H. MF59 adjuvant enhances anticapsular antibody responses of infant primates vaccinated with meningococcal C (MenC) and Haemophilus type b (Hib) oligosaccharide (OS)-protein conjugate vaccines [Abstract]. Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans; September 15-18, 1996. American Society for Microbiology, 1996:155.